Patient Group Direction for COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [recombinant])

Document first published:
Page updated:
Topic:
,
Publication type:

This Patient Group Direction (PGD) is for the administration of COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) to individuals in accordance with the national COVID-19 vaccination programme.

Published 6 January 2021, updated 23 March and 28 April 2021.